Julio Gonzalez Honored by Hispanic 100 Foundation with American Legacy of Excellence in Business Award

Engineered Tax Services founder recognized at Night of Distinction Gala during America’s 250th anniversary year.

West Palm Beach, Florida – Julio Gonzalez, founder and CEO of Engineered Tax Services (ETS), received the American Legacy of Excellence in Business award from the Hispanic 100 Foundation at the Night of Distinction Gala held May 20 at the Waldorf Astoria in Washington, D.C. The award honors business figures who have widened access to financial opportunity, created jobs, and contributed to community growth.

The gala took place during the lead-up to America’s 250th anniversary and brought together entrepreneurs, executives, and public-sector figures for an evening centered on legacy, service, and economic contribution. Gonzalez was honored alongside other business and community leaders selected by the Hispanic 100 Foundation for their role in shaping opportunity across the country.

Gonzalez was selected for his 25-year record of helping U.S. companies reduce tax liability and reinvest those savings into expansion. Under his leadership, ETS has grown to 26 offices, served more than 1,000 clients, and produced over 2 billion dollars in tax savings.

The firm specializes in engineering-based tax studies, including cost segregation, energy tax incentives, and research and development tax credits. ETS works with commercial property owners, real estate investors, manufacturers, and operating businesses across multiple sectors.

“Being recognized by the Hispanic 100 Foundation is more than an award. It is a reminder of why we do what we do,” said Gonzalez. “This journey has never been about accolades. It is about creating opportunities, leveling the playing field, and building a legacy that empowers others to win.”

Beyond ETS, Gonzalez has published two books focused on widening access to wealth-building tools. Why Billionaires Love the Tax Code explains how high-net-worth families and businesses apply existing tax law to compound capital. The Grant Equality Blueprint outlines how entrepreneurs and underserved communities can locate and qualify for federal and state grant programs.

Both titles reflect a position Gonzalez has held throughout his career: that tax and grant strategy should not sit behind a wall of complexity, and that small businesses deserve the same planning tools used by larger firms.

The Hispanic 100 Foundation hosts the Night of Distinction Gala to recognize business and community figures whose work has shaped opportunity for the next generation. The 2026 edition carried added weight as a tribute to American legacy and a celebration of the country’s 250th year.

“As the country celebrates its 250th anniversary, I am proud to stand alongside leaders who believe in freedom, opportunity, and the power of hard work,” Gonzalez said. “To my team, our clients, and the community we serve, thank you. This is just the beginning.”

About Engineered Tax Services

Founded by Julio Gonzalez and headquartered in West Palm Beach, Florida, Engineered Tax Services is a national tax consulting firm offering engineering-based studies and specialty tax planning to U.S. businesses, property owners, and real estate investors. Service lines include cost segregation, energy tax incentives, research and development credits, and grant consulting. ETS serves more than 1,000 clients across 26 offices and has produced over 2 billion dollars in client tax savings.

Credits: The KR Media Group.

Media Contact
Company Name: Engineered Tax Services
Contact Person: Julio Gonzalez
Email: Send Email
City: West Palm Beach
State: Florida
Country: United States
Website: engineeredtaxservices.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Julio Gonzalez Honored by Hispanic 100 Foundation with American Legacy of Excellence in Business Award

Hanron Factory – A Leading Manufacturer Of High-Quality LED Strip Lights

A professional LED strip manufacturer, high-quality custom LED lighting solutions are what Hanron Factory offers. Starting operations in 2010, the company continues to innovate various LED lighting solutions so customers find what they need.

As a top LED strip light manufacturer, Hanron Factory maintains a smooth production process. Hanron Factory handles each production step, from designing to supplying, to ensure everything goes right. The company has an expert team who are responsible for the production process.

Hanron Factory specializes in LED strips and neon lights, solidifying its market position. A reputable name, Hanron Factory not only dominates the China LED stripmarket but also the global lighting industry. This is why customers trust Hanron Factory over other brands.

Hanron Factory is run by a team of 100 professionals. From technical engineers to sales engineers, the team consists of talented staff who are committed to the company’s excellence. This makes Hanron Factory a powerful contender in the global lighting industry.

Keeping up with their reputation to maintain the highest production standards, Hanron Factory ensures customers get top-notch products at a reasonable price. The company has an ISO9001:2015 certification and its products comply with major international certifications like RoHS, BIS, ETL, CE, LM80, Reach, and TUV CB. This ensures top-tier quality and safety, which many other companies fail to provide.

A leading LED strip manufacturer, Hanron Factory has over 15 years of industry experience. Serving more than 500 customers and expanding its presence across 70+ countries and regions has helped the company establish itself as a global leader. Today, Hanron Factory makes various LED lighting solutions suitable for a variety of applications.

With a portfolio of over 2,000 LED strip light models, Hanron Factory meets commercial and residential lighting demands. One of their popular products is ws2815, which customers prefer. In addition, Hanron Factory offers lighting solutions for industrial and automotive projects.

Hanron Factory aims to diversify its product range by specializing in various LED strip lights. Their models including WS2815, WS2811, WS2812B, and SK6812 are high-quality LED strips designed to last for an extended period. The company also provides specialized solutions like DMX512 LED strips, breakpoint resume series, and LED pixel screens.

A key strength is customized LED strip lights, making Hanron Factory stand out from similar brands. The in-house team customizes LED lighting solutions according to customers’ requirements, making them a preferred choice among customers, especially those who seek unique lighting solutions.

Providing tailored solutions is easy because of Hanron Factory’s team. Not only is their team experienced, but they also listen to customers’ requests. As a result, Hanron Factory provides PCB design support and tailored solutions without hassles. From pixel IC to color and size, Hanron Factory customizes every aspect of LED strip lights.

Promising to meet customers’ unique needs, Hanron Factory moves forward. Be it an architectural space, retail signage, or industrial application, ensuring each project receives the perfect lighting solution is what Hanron Factory does. Additionally, customers get a 3–5 year warranty on all LED strip lights.

Media Contact
Company Name: ledstrip lightings
Email: Send Email
Country: United States
Website: https://www.ledstriplightings.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hanron Factory – A Leading Manufacturer Of High-Quality LED Strip Lights

AV Access Launches Sports Bar AV Upgrade Program with 4KIP200 for FIFA World Cup 2026

“”Sports bars gearing up for FIFA World Cup 2026 have dozens of screens and multiple cable boxes — the 4KIP200 HDMI over IP system connects them all through a single Ethernet switch and delivers crystal-clear 4K to every TV in the venue, zero configuration required,” said Bill Liao, CTO at AV Access.”
AV Access arms sports bars for FIFA World Cup 2026 with the 4KIP200 HDMI over IP — the simplest way to distribute 4K live feeds across every screen, with zero configuration where traditional systems take hours.

AV Access, a leading provider of Pro AV and AV over IP solutions, announced the launch of its Sports Bar Viewing Upgrade Program for FIFA World Cup 2026, spotlighting the 4KIP200 HDMI over IP series — a 4K video distribution solution with zero switch configurationthat’s easy to deploy and manage.

“With the 2026 FIFA World Cup just around the corner, a stadium-level4K viewing experience is no longer a nice-to-have — it’s what fills seats and keeps customers coming back. We’re proud the 4KIP200 system makes it effortless for any sports bar to get there,” said Bill Liao, CTO at AV Access.

The Biggest World Cup Ever Demands the Best AV Infrastructure

Drawing an estimated five billion global viewers across 104 matches and 16 U.S. host cities, the 2026 FIFA World Cup is the single largest revenue opportunity for sports bars in a generation. Overlapping kickoffs mean venues must run different live feeds across dozens of screens simultaneously — exactly where traditional AV matrix systems fall short, and the 4KIP200 AV over IP solution steps in.

No Configuration Required — Truly Plug-and-Play AV Solution

Despite kickoff being less than a month away, sports bars still have time to upgrade. The 4KIP200 ships ready to go — plug it into any standard Ethernet switch, connect the screens, and the system is live. Bar managers then run everything from an iPad via the VDirector App — switching sources, building video walls up to 8×8, all with a drag and drop. It’s plug-and-play, not a days-long project.

Art & Jake’s Sports Bar rolled out the 4KIP200 across two 2,000-square-foot Michigan locations — 34 encoders, 148 decoders, every screen live by January 2026. Proof that stadium-level 4K doesn’t have to be complicated,” added Bill. Partner pricing and volume discounts are available through the World Cup Sports Bar Viewing Upgrade Program.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP solutions, including HDMI/KVM extenders, splitters, switchers, KVM switches, and wireless conferencing systems. Dedicated to delivering the ultimate audiovisual experience through easy-to-install, quality-assured products at honest pricing. Learn more at www.avaccess.com.

Media Contact
Company Name: ACTIONS GLOBAL US INC
Contact Person: Nada Xi
Email: Send Email
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Launches Sports Bar AV Upgrade Program with 4KIP200 for FIFA World Cup 2026

Best Portable Storage Companies (2026): Report Published by Kinross Research

Kinross Research Publishes Its Latest Research Report Recognizing UNITS® Moving and Portable Storage as the Best Portable Storage Companies (2026)

Kinross Research has published a new in-depth market report titled “Best Portable Storage Companies,” analyzing the leading providers shaping the portable storage and moving industry across the United States.

The report evaluates major portable storage companies based on container durability, transportation systems, customer service quality, geographic availability, pricing structure, storage flexibility, and long-distance moving capabilities.

After extensive market analysis, UNITS® Moving and Portable Storage earned the top position in the rankings due to its combination of customer-focused logistics, durable storage containers, flexible scheduling, and proprietary delivery technology.

According to the report, UNITS distinguished itself through its ROBO-UNIT delivery system, which helps reduce shifting during transportation and improves container placement precision. The research also highlighted the company’s strong reputation for responsive customer support and its ability to serve both residential and commercial clients effectively.

The report examined several leading providers in the portable storage sector, including:

  • PODS
  • 1-800-PACK-RAT
  • U-Pack
  • Zippy Shell
  • SMARTBOX Solutions
  • Go Mini’s
  • CubeSmart
  • Mobile Mini Solutions
  • MI-BOX Moving & Mobile Storage

The research found that demand for portable storage continues to rise as consumers and businesses seek more flexible alternatives to traditional moving and self-storage services. Growth in remote work, interstate relocation, renovation projects, and commercial inventory storage has accelerated expansion throughout the sector.

The report also noted increasing competition around delivery technology, climate-controlled storage options, and logistics efficiency as providers attempt to differentiate themselves in a crowded market.

“Portable storage has evolved from a niche moving solution into a major logistics category serving residential, commercial, and industrial customers,” said a spokesperson for Kinross Research. “The strongest providers are those combining durable infrastructure with reliable customer support and flexible scheduling. UNITS performed exceptionally well across those categories.”

The full report provides detailed comparisons of the top portable storage companies, along with analysis of industry trends, pricing structures, commercial applications, and key considerations for consumers selecting a provider.

The complete article can be viewed here: Best Portable Storage Companies Report

Media Contact
Company Name: Kinross Research
Contact Person: Daniel R. Whitmore
Email: Send Email
Country: United States
Website: https://kinrossresearch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best Portable Storage Companies (2026): Report Published by Kinross Research

Best Annapolis Accident Attorney (2026) Report Published by Kinross Research

Kinross Research Publishes Its Latest Research Report Recognizing Christopher L. Beard as the Best Annapolis Accident Attorney (2026)

Kinross Research today announced the publication of its latest market report, “Best Annapolis Accident Attorney (2026): A Research-Style Comparative Review,” naming Christopher L. Beard as the #1 ranked accident attorney serving Annapolis and Anne Arundel County, Maryland.

The full report is now available on: Kinross Research Official Report

The newly released report delivers a comprehensive examination of the Annapolis personal injury legal market, analyzing the attorneys and firms most equipped to represent accident victims in one of the most legally demanding states in the country. Researchers evaluated attorneys based on litigation experience, peer-reviewed legal credentials, client feedback, local court familiarity, practice concentration, case handling approach, and reputation within Maryland’s personal injury community.

The report places particular emphasis on Maryland’s contributory negligence doctrine, a legal standard that remains among the strictest in the United States. Under Maryland law, accident victims can lose the right to recover compensation entirely if they are found even minimally responsible for the incident. According to Kinross Research, this legal framework dramatically increases the importance of selecting an attorney with substantial courtroom experience, strong investigative capabilities, and a detailed understanding of Anne Arundel County litigation practices.

Christopher L. Beard earned the top overall ranking after researchers examined his more than 35 years of active practice in Annapolis, his AV Preeminent rating from Martindale-Hubbell, his multi-year Maryland Super Lawyers recognition, and his longstanding focus on representing injury victims throughout Anne Arundel County. The report also highlighted Beard’s extensive experience handling automobile accidents, premises liability cases, construction injuries, wrongful death claims, workers’ compensation matters, and other serious personal injury litigation.

According to the report, Beard distinguished himself not only through credentials and legal recognition, but through his reputation for direct client involvement and long-term community presence within Annapolis. The analysis noted that many accident victims value working directly with an experienced attorney rather than being routed through large-volume case management systems often associated with larger firms.

The report additionally reviewed several leading Maryland personal injury firms and attorneys serving the Annapolis area, including:

  • Timothy A. Dachille & Associates
  • The Ingram Firm, LLC
  • Plaxen Adler Muncy, P.A.
  • Patterson Law
  • Cochran & Chhabra, LLC
  • Hyatt & Weber Injury Law
  • Price Benowitz Accident Injury Lawyers, LLP

Researchers also analyzed broader accident and litigation trends affecting Annapolis and Anne Arundel County, including increased traffic volume along Route 50 and Interstate 97, commercial trucking collisions, motorcycle accidents, premises liability claims, and boating-related injury cases connected to Annapolis’s waterfront and tourism economy. The report references publicly available crash statistics and legal precedent shaping accident litigation throughout Maryland.

“Maryland’s contributory negligence standard creates one of the toughest personal injury environments in the country,” said a spokesperson for Kinross Research. “The purpose of this report was to identify the attorneys with the strongest track records, courtroom experience, and local knowledge to help consumers make informed decisions after serious accidents. Annapolis accident victims face very different legal risks than victims in comparative negligence states, and attorney selection can directly affect whether compensation is recovered at all.”

In addition to ranking attorneys, the report includes educational analysis covering Maryland accident law, common accident types in the Annapolis area, claim timelines, insurance company tactics, and practical guidance for accident victims navigating the legal process following serious injuries.

The full report is now available on: https://kinrossresearch.com/best-annapolis-accident-attorney/

Media Contact
Company Name: Kinross Research
Contact Person: Daniel R. Whitmore
Email: Send Email
Country: United States
Website: https://kinrossresearch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best Annapolis Accident Attorney (2026) Report Published by Kinross Research

What Is the Best Alternative to TaskRabbit, Thumbtack, and Angi in 2026? Workers and Homeowners Are Choosing GigNGo

“GigNGo — The Commission-Free Alternative to TaskRabbit, Thumbtack, and Angi”
TaskRabbit fees, Thumbtack lead charges, and Angi commissions are pushing workers and homeowners to look for something better. GigNGo is a commission-free, video-first local services marketplace where workers keep 100% of their earnings and homeowners see who they’re hiring before they commit.

GRAND RAPIDS, MI – May 27, 2026 – If you have ever searched for a local handyman, house cleaner, or lawn care professional online, you have almost certainly landed on TaskRabbit, Thumbtack, or Angi. They are the dominant names in local services hiring. They are also, increasingly, the platforms that workers and homeowners are actively searching for alternatives to.

The reasons are not hard to find.

TaskRabbit charges workers a service fee on every job completed — a percentage that reduces take-home pay on every single transaction. Thumbtack sells leads, meaning workers pay just to be considered for a job, with no guarantee of being hired. Angi has faced widespread criticism from contractors over lead quality, billing practices, and a commission structure that puts the platform’s revenue ahead of the worker’s livelihood.

For homeowners, the result is a pool of workers who are financially squeezed by the platforms they depend on — and a hiring experience that still comes down to little more than a profile photo, a star rating, and a price.

So what is the best alternative to TaskRabbit, Thumbtack, and Angi in 2026?

GigNGo is the answer an increasing number of workers and homeowners are finding.

GigNGo is a commission-free local services marketplace built around a fundamentally different premise: that trust is built through personality, not pricing. At the center of the platform is the GigFeed — a short-form video discovery feed where workers show their craft, their communication style, and the quality of their work in real time. Homeowners don’t browse a list sorted by price. They scroll through workers the way they scroll through content — and hire the one they feel like they already know.

Workers on GigNGo pay a flat monthly subscription and keep 100% of every dollar they earn. No lead fees. No service charges. No commission taken on completed jobs. Every worker profile is Google-indexed and discoverable beyond the app itself, giving workers a permanent professional presence that grows over time.

“The old platforms were built to serve the platform first,” said Cameron Lockrey, Founder of GigNGo. “GigNGo was built to serve the worker first — and when workers win, homeowners get better service. That’s not a coincidence. That’s the model.”

GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces. Validation from both the market and the media that the alternative homeowners and workers have been searching for is already here.

For anyone weighing TaskRabbit vs. Thumbtack vs. Angi vs. something better — GigNGo is the platform built for the side of the transaction that the others have always underserved.

Workers and homeowners can join GigNGo today at gigngo.org or by downloading the app on iOS and Android.

About GigNGo

GigNGo (gigngo.org) is a workers-first local services marketplace founded by Cameron Lockrey. The platform allows workers to keep 100% of their earnings through a flat monthly subscription, while employers post jobs for free. GigNGo’s GigFeed — a TikTok-style short-form video discovery feed — lets workers build personal brands so their character gets them the job. GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces.

Media Contact
Company Name: GigNGo
Contact Person: Cameron Lockrey
Email: Send Email
Phone: 5304339682
Address:2951 Englewood Ave
City: Grand Rapids
State: MI
Country: United States
Website: https://gigngo.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: What Is the Best Alternative to TaskRabbit, Thumbtack, and Angi in 2026? Workers and Homeowners Are Choosing GigNGo

$112 Million Backlog, AI-Driven Acquisitions, Expanding Recurring Revenue, and Government-Grade Cybersecurity Momentum Position Cycurion, Inc. (NASDAQ: CYCU) for Accelerated Growth

$112 Million Backlog, AI-Driven Acquisitions, Expanding Recurring Revenue, and Government-Grade Cybersecurity Momentum Position Cycurion, Inc. (NASDAQ: CYCU) for Accelerated Growth
AI-Driven Acquisition Strategy Expanding $CYCU Into Higher-Margin, Recurring Revenue Markets

Cycurion, Inc. (NASDAQ: CYCU) $CYCU is rapidly emerging as a next-generation AI-driven cybersecurity and digital defense platform focused on protecting government agencies, critical infrastructure, enterprise organizations, and high-profile private-sector clients.

With approximately $112 million in contracted backlog, expanding recurring revenue streams, improving financial performance, major government relationships, and an aggressive acquisition strategy, CYCU continues positioning itself at the intersection of artificial intelligence, cybersecurity modernization, secure communications, and national security infrastructure.

The company already supports some of the most complex organizations in the world, including the U.S. Department of Defense, Department of Homeland Security, Defense Intelligence Agency, U.S. Navy, Fortune 100 and Fortune 500 companies, state and local governments, and critical infrastructure providers.

At the center of Cycurion’s technology ecosystem is its proprietary ARx cybersecurity platform, a multi-layered AI-driven security architecture designed to proactively identify, monitor, defend against, and neutralize cyber threats in real time. The platform is engineered to protect sensitive digital assets without requiring invasive hardware installations or large-scale cloud migrations, making deployment faster and more efficient for enterprise and government customers.

AI-Driven Acquisition Strategy

One of the company’s most significant strategic initiatives in 2026 has been its aggressive expansion through acquisitions designed to enhance recurring revenue, expand AI capabilities, and broaden CYCU’s addressable market.

Halo Privacy and HavenX Acquisition

Cycurion recently announced a binding agreement to acquire Halo Privacy and fully integrate HavenX, creating what management describes as a powerful AI-driven platform for secure communications, digital defense, attribution intelligence, and proactive threat mitigation. (stocktitan.net)

Halo Privacy generated approximately $7 million in revenue, including roughly $5.5 million in high-quality annual recurring revenue, while maintaining strong gross margins. Approximately 95% of Halo’s revenue currently originates from U.S. government contracts, adding meaningful recurring revenue visibility and long-term stability to CYCU’s financial profile.

The acquisition also introduces Halo Link, a secure encrypted messaging and voice communications platform engineered for government agencies, enterprise clients, executives, and privacy-focused users seeking secure communications and advanced cyber protection.

The integration of HavenX significantly expands CYCU’s capabilities through advanced OSINT intelligence, cyber-harassment attribution, digital investigations, IP geolocation, breach-data correlation, and threat actor identification technologies.

Management believes the combined platform creates substantial cross-selling opportunities while dramatically expanding CYCU’s reach beyond traditional government contracts into private-sector verticals including healthcare, financial institutions, law firms, research organizations, corporate executives, and high-net-worth individuals.

Secuvant Acquisition Expands Federal Cybersecurity Footprint

Cycurion additionally announced the acquisition of Secuvant, a Department of Defense-focused cybersecurity and federal services company designed to strengthen CYCU’s sovereign cloud security and AI-driven defense capabilities. (ca.investing.com)

Management believes the acquisition further enhances the company’s position within federal cybersecurity infrastructure and strengthens its long-term strategy of consolidating high-margin cybersecurity assets under the proprietary ARx platform.

Kustom Entertainment Video Solutions Transaction

Earlier this year, CYCU also announced a Memorandum of Understanding to acquire the video-solutions division of Kustom Entertainment. (nasdaq.com)

The transaction is expected to contribute approximately $5.1 million in annual revenue and an estimated $8 million backlog while further diversifying the company’s public safety, surveillance, and cybersecurity ecosystem.

Management believes the acquisition could create additional recurring subscription revenue opportunities, integrated public safety solutions, and operational synergies across government and enterprise customers.

Financial Turnaround and Margin Expansion Showing Strong Momentum

Cycurion’s first quarter 2026 results demonstrated significant operational improvement and continued execution of management’s profitability strategy. (chartmill.com)

First quarter highlights included:

• Revenue of approximately $3.3 million • Gross margin expansion of 900 basis points to 21.1% • SG&A reduction of 31.6% • Net loss improvement of 51.5% • EBITDA loss improvement of 60.2%

Management attributes the operational improvements to strategic restructuring initiatives, disciplined cost controls, increasing focus on higher-margin contracts, and expanding recurring revenue opportunities.

Cycurion has also stated that it now has meaningful visibility toward approximately $21 million to $22 million in annual revenue as its acquisition strategy and backlog continue expanding.

$112 Million Contract Backlog Provides Long-Term Revenue Visibility

In April 2026, Cycurion announced a $6 million purchase order under a Master Services Agreement / Indefinite Delivery Indefinite Quantity contract with a major U.S. municipality. (stocktitan.net)

The contract further expands CYCU’s cybersecurity, consulting, analytics, and IT services footprint while increasing the company’s already substantial backlog.

According to CEO Kevin Kelly, Cycurion now has approximately $112 million in contracted backlog, creating multi-year revenue visibility and supporting management’s long-term growth strategy.

Management additionally stated that approximately $15 million to $17 million in revenue is already positioned for each of 2026, 2027, and 2028.

Multi-Year Fortune 500 Partnership Expands AI Footprint

Cycurion also recently announced a strategic multi-year partnership with a Fortune 500 company supporting a major U.S. government agency. (nasdaq.com)

The agreement includes a minimum five-year term, with CYCU’s portion initially valued at approximately $1 million in the first year and meaningful expansion potential moving forward.

Management believes the partnership further validates CYCU’s AI-driven cybersecurity capabilities and strengthens the company’s positioning within high-security government modernization initiatives.

Expansion Into Public Health and Government Markets

The company has continued expanding its presence within public health and state government sectors through additional multi-year cybersecurity awards expected to generate recurring annual revenue. (stocktitan.net)

CYCU has also secured statewide consulting and cybersecurity relationships while continuing expanding across municipal, education, healthcare, and public safety verticals.

Positioned at the Intersection of AI, Cybersecurity, National Security, and Secure Communications

As cyber threats continue escalating globally, demand for AI-driven cybersecurity infrastructure, secure communications, digital attribution systems, and advanced privacy technologies continues accelerating across both government and private-sector markets.

Cycurion appears strategically positioned at the center of several major long-term technology trends, including:

• AI-driven cybersecurity • Government digital modernization • National security infrastructure • Secure communications • Digital privacy • Cyber attribution and investigations • Critical infrastructure protection • Sovereign cloud security • Managed cybersecurity services • Public safety technology

With expanding recurring revenue, improving margins, aggressive acquisition activity, growing government relationships, and increasing backlog visibility, CYCU is rapidly evolving into a diversified AI-enabled cybersecurity and digital defense platform.

Management continues emphasizing long-term scalable growth, operational efficiency, recurring revenue expansion, and strategic acquisitions designed to create what could become one of the more differentiated emerging cybersecurity platforms in the public markets.

For more information on $CYCU visit: www.cycurion.com

EMAIL: info@cycurion.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Cycurion, Inc.
Contact Person: Kevin Kelly, Chairman & CEO
Email: Send Email
Phone: 888-341-6680
Address:1640 Boro Place 4th Floor
City: McLean
State: Virginia
Country: United States
Website: www.cycurion.com

PEComa Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Aadi Bioscience, Sarcoma Oncology, Novartis

The Key PEComa Companies in the market include – Aadi Bioscience, Sarcoma Oncology, Novartis, and others.

 

DelveInsight’s report, “PEComa Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the PEComa landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines PEComa market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

Get a Free sample for the PEComa Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pecoma-market

 

Some of the key facts of the PEComa Market Report:

  • The PEComa market size was valued at nearly USD 45 million in 2025 and is anticipated to reach approximately USD 135 million by 2036, expanding at a CAGR of 8.1% during the 2026–2036 forecast period.

  • In March 2025, Aadi Bioscience has been reorganized into two entities. Following the divestiture of Aadi Sub to KAKEN, KAKEN assumes ownership of Aadi Sub, including the Aadi name, trademark, and the FYARRO® business. The remaining parent company has been renamed Whitehawk Therapeutics, focusing on its portfolio of ADC assets.

  • In December 2024, Aadi Bioscience entered an agreement to sell its commercial drug FYARRO to KAKEN Pharmaceutical for USD 100 million, alongside a USD 100 million PIPE equity financing and an exclusive license for a three-asset preclinical ADC portfolio in collaboration with WuXi Biologics and Hangzhou DAC. In March 2025, the company’s stockholders approved the sale of FYARRO to KAKEN.

  • According to the estimates, the largest market size of PEComa was captured by the United States, i.e., ~USD 114 million by 2036.

  • The PEComa treatment landscape is evolving as management shifts from conventional approaches toward more molecularly targeted strategies, with mTOR inhibitors such as Sirolimus and Everolimus driving adoption due to their demonstrated efficacy in TSC1/TSC2-altered tumors, while emerging use of immunotherapies like Keytruda and other precision approaches is gaining interest in advanced or refractory cases.

  • Regional market dynamics for PEComa show the United States leading in revenue, while markets in Japan and European Union demonstrate steady growth, reflecting improved diagnostic awareness, greater access to targeted therapies and increasing adoption of emerging treatment approaches in rare tumor management.

  • In 2036, among all the therapies for PEComa, the highest revenue is estimated to be generated by FYARRO, in the United States.

  • According to DelveInsight’s estimates, the total prevalent cases of PEComa in the 7MM were approximately 408 in 2025.

  • Among EU4 and the UK, Germany accounts for the highest incidence of PEComas, followed by France and the UK.

  • In 2025, Perivascular Epithelioid Cell Neoplasm (PEComa) by stage in the US, benign tumor is the most prevalent subtype with ~67% followed by local aggressive behavior (malignant PEComa) accounting for ~33%.

  • The observed female predominance and earlier onset of PEComa highlight the importance of gender-specific screening and early intervention strategies, particularly in recognizing susceptibility patterns and addressing disease at onset to prevent long-term complications.

  • Aadi Bioscience’s FYARRO is the only approved therapy for PEComa.

  • Key PEComa Companies: Aadi Bioscience, Sarcoma Oncology, Novartis, and others

  • Key PEComa Therapies: FYARRO (sirolimus protein-bound), Nab-Rapamycin, Everolimus, and others

  • The PEComa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PEComa pipeline products will significantly revolutionize the PEComa market dynamics.

 

PEComa Overview

PEComa (Perivascular Epithelioid Cell Tumor) is a rare type of mesenchymal tumor that arises from perivascular epithelioid cells specialized cells typically located around blood vessels. These tumors can develop in various parts of the body, including the kidneys, liver, lungs, uterus, gastrointestinal tract, and soft tissues. PEComas belong to a broader group of tumors known as PEComatous tumors, which also includes angiomyolipoma and lymphangioleiomyomatosis.

PEComa is considered a rare cancer, and its exact cause is not fully understood. However, some cases are associated with genetic mutations linked to tuberous sclerosis complex (TSC), which affects the mTOR signaling pathway involved in cell growth and proliferation. Because of this pathway involvement, mTOR inhibitors have become an important targeted treatment option.

 

To Know in detail about the PEComa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PEComa Market Forecast

 

PEComa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

PEComa Epidemiology Segmentation:

The PEComa market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of PEComa

  • Prevalent Cases of PEComa by severity

  • Gender-specific Prevalence of PEComa

  • Diagnosed Cases of Episodic and Chronic PEComa

 

Download the report to understand which factors are driving PEComa epidemiology trends @ PEComa Epidemiology Forecast

 

PEComa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PEComa market or expected to get launched during the study period. The analysis covers PEComa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the PEComa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

PEComa Therapies and Key Companies

  • Sirolimus protein-bound/ABI-009 (FYARRO): Kaken Pharmaceuticals

  • Pembrolizumab (KEYTRUDA): Merck Sharp & Dohme

  • FYARRO (sirolimus protein-bound): Aadi Bioscience

  • Nab-Rapamycin: Sarcoma Oncology

  • Everolimus: Novartis

 

Discover more about therapies set to grab major PEComa market share @ PEComa Treatment Landscape

 

PEComa Market Drivers

  • Increasing awareness of rare cancers, leading to improved diagnosis and reporting of PEComa cases.

  • Advancements in targeted therapies, particularly the development and use of mTOR inhibitors for PEComa treatment.

  • Growing investment in rare disease research and drug development by pharmaceutical and biotechnology companies.

  • Regulatory incentives for orphan drugs, encouraging companies to develop therapies for rare tumors like PEComa.

  • Rising number of clinical trials exploring novel targeted therapies and immunotherapies.

 

PEComa Market Barriers

  • Extremely small patient population, which limits large-scale clinical trials and commercial opportunities.

  • Limited approved treatment options, resulting in reliance on off-label therapies or experimental treatments.

  • High cost of targeted therapies, which can restrict patient access in some regions.

  • Challenges in early diagnosis, as PEComa symptoms are often nonspecific and the disease is rare.

  • Lack of standardized treatment guidelines due to limited clinical data and case studies.

 

Scope of the PEComa Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key PEComa Companies: Aadi Bioscience, Sarcoma Oncology, Novartis, and others

  • Key PEComa Therapies: FYARRO (sirolimus protein-bound), Nab-Rapamycin, Everolimus, and others

  • PEComa Therapeutic Assessment: PEComa current marketed and PEComa emerging therapies

  • PEComa Market Dynamics: PEComa market drivers and PEComa market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • PEComa Unmet Needs, KOL’s views, Analyst’s views, PEComa Market Access and Reimbursement

 

To know more about PEComa companies working in the treatment market, visit @ PEComa Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. PEComa Market Report Introduction

2. Executive Summary for PEComa

3. SWOT analysis of PEComa

4. PEComa Patient Share (%) Overview at a Glance

5. PEComa Market Overview at a Glance

6. PEComa Disease Background and Overview

7. PEComa Epidemiology and Patient Population

8. Country-Specific Patient Population of PEComa

9. PEComa Current Treatment and Medical Practices

10. PEComa Unmet Needs

11. PEComa Emerging Therapies

12. PEComa Market Outlook

13. Country-Wise PEComa Market Analysis (2022–2036)

14. PEComa Market Access and Reimbursement of Therapies

15. PEComa Market Drivers

16. PEComa Market Barriers

17. PEComa Appendix

18. PEComa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PEComa Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Aadi Bioscience, Sarcoma Oncology, Novartis

Influenza A Infections Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen R&D, Ainos, Genentech, TaiGen Biotechnology

The Key Influenza A Infections Companies in the market include – Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others .

 

The Influenza A Infections market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.

 

DelveInsight’s “Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Get a Free sample for the Influenza A Infections Market Report

https://www.delveinsight.com/sample-request/influenza-a-infections-market

 

Some of the key facts of the Influenza A Infections Market Report:

  • The Influenza A market size was valued at nearly USD 5 billion in 2025 and is expected to reach approximately USD 10 billion by 2036, registering a CAGR of 7.9% during the forecast period from 2026 to 2036.

  • In February 2026, Cidara Therapeutics announced MK-1406 (CD388) is currently being evaluated in the Phase 3 ANCHOR study (NCT07159763).

  • In January 2026, Merck announced The company has successfully completed a cash tender offer, conducted via its subsidiary, for the acquisition of all outstanding common shares of Cidara Therapeutics.

  • In March 2026, Cocrystalpharma announced The company plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A with an additional Phase 2a study.

  • In February 2026, The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for mCombriax, a vaccine developed by Moderna, for the prevention of influenza disease.

  • In March 2025, Cidara Therapeutics announced two upcoming presentations on CD388 in Influenza at the 38th International Conference on Antiviral Research (ICAR).

  • In April 2025, Roche announced that New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza showing a reduction in the transmission of influenza viruses.

  • In the United States, the vaccinated population was highest among adults aged 18–49 years, while the lowest vaccination uptake was observed in pregnant women in 2025; overall, the vaccinated pool was segmented across children (0–4, 5–12 years), adolescents (13–17 years), adults (18–49, 50–64, ≥65 years), and pregnant women.

  • In 2025, the influenza vaccine failure rate in the United States was estimated to be approximately 70%, indicating a substantial proportion of vaccinated individuals remained susceptible to infection.

  • By conducting secondary analysis of publicly available surveillance data In Japan, it was observed that in Japan according to the Ministry of Health, Labour and Welfare, the average approximately 196,895 weekly influenza cases were reported in November 2025, corresponding to an average of 51.12 cases per medical institution, indicating high epidemic intensity

  • In Europe, influenza A (H1N1)pdm09 emerged as the predominant subtype in 2024, accounting for approximately 57–93% of all influenza A cases, as reported by the European Respiratory Virus Surveillance Summary (ERVISS) (2025).

  • In the United States, the total number of influenza A positive cases is projected to increase over the study period from 2022 to 2036, reflecting a rising disease burden over time.

  • Key Influenza A Infections Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others

  • Key Influenza A Infections Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, Ingavirin, Neumifil, mRNA-1010, JNJ-63623872, Oseltamivir, MHAA4549A, TG-1000, Zanamivir, and others

 

Influenza A Infections Overview

Influenza A infections are caused by the influenza A virus, a highly contagious respiratory pathogen responsible for seasonal flu epidemics and occasional pandemics. It infects the nose, throat, and lungs, leading to symptoms such as fever, cough, sore throat, body aches, and fatigue. Severe cases can result in complications like pneumonia, particularly in young children, the elderly, and individuals with weakened immune systems.

 

To Know in detail about the Influenza A Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Influenza A Infections Market Insights

 

Influenza A Infections Epidemiology Segmentation:

The Influenza A Infections market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of Influenza A Infections

  • Prevalent Cases of Influenza A Infections by severity

  • Gender-specific Prevalence of Influenza A Infections

  • Diagnosed Cases of Episodic and Chronic Influenza A Infections

 

Download the report to understand which factors are driving Influenza A Infections epidemiology trends @ Influenza A Infections Epidemiological Insights

 

Influenza A Infections Market

The dynamics of the Influenza A Infections market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2022-2036.

 

Influenza A Infections Therapies and Key Companies

  • XOFLUZA (baloxavir marboxil): Roche and Shionogi

  • CC-42344: Cocrystal Pharma

  • CD388: Cidara Therapeutics

  • mRNA-1010: Moderna

  • Flu Pandemic mRNA (GSK4382276A): GlaxoSmithKline

  • RAPIVAB (peramivir): BioCryst Pharmaceuticals

  • FLUAD QUADRIVALENT: Seqirus

  • Ingavirin: Valenta Pharm JSC

  • Neumifil: Pneumagen

  • mRNA-1010: ModernaTX

  • JNJ-63623872: Janssen Research & Development, LLC

  • Oseltamivir: Ainos, Inc.

  • MHAA4549A: Genentech, Inc.

  • TG-1000: TaiGen Biotechnology Co., Ltd.

  • Zanamivir: Jiangsu Simcere Pharmaceutical Co., Ltd.

 

To know more about Influenza A Infections treatment, visit @ Influenza A Infections Medications

 

Influenza A Infections Market Strengths

  • The rising prevalence of Influenza is the major factors driving the growth of the treatment market

  • The presence of a large number of manufacturers is further boosting the growth of the treatment market

 

Influenza A Infections Market Barriers

  • Influenza A Infections key players are heavily investing in research activities to expand the therapeutic application for treatment drugs which in turn are creating more scopes and opportunities for the growth of Influenza A Infections treatment market

 

Scope of the Influenza A Infections Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Influenza A Infections Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., and others

  • Key Influenza A Infections Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, Ingavirin, Neumifil, mRNA-1010, JNJ-63623872, Oseltamivir, MHAA4549A, TG-1000, Zanamivir, and others

  • Influenza A Infections Therapeutic Assessment: Influenza A Infections current marketed and Influenza A Infections emerging therapies

  • Influenza A Infections Market Dynamics: Influenza A Infections market drivers and Influenza A Infections market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Influenza A Infections Unmet Needs, KOL’s views, Analyst’s views, Influenza A Infections Market Access and Reimbursement

 

Discover more about therapies set to grab major Influenza A Infections market share @ Influenza A Infections Treatment Landscape

 

Table of Contents

1. Influenza A Infections Market Report Introduction

2. Executive Summary for Influenza A Infections

3. SWOT analysis of Influenza A Infections

4. Influenza A Infections Patient Share (%) Overview at a Glance

5. Influenza A Infections Market Overview at a Glance

6. Influenza A Infections Disease Background and Overview

7. Influenza A Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Influenza A Infections

9. Influenza A Infections Current Treatment and Medical Practices

10. Influenza A Infections Unmet Needs

11. Influenza A Infections Emerging Therapies

12. Influenza A Infections Market Outlook

13. Country-Wise Influenza A Infections Market Analysis (2022–2036)

14. Influenza A Infections Market Access and Reimbursement of Therapies

15. Influenza A Infections Market Drivers

16. Influenza A Infections Market Barriers

17. Influenza A Infections Appendix

18. Influenza A Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Influenza A Infections Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen R&D, Ainos, Genentech, TaiGen Biotechnology

Familial Chylomicronemia Syndrome Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics

The Key Familial Chylomicronemia Syndrome Companies in the amrket include – Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others.

 

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Familial Chylomicronemia Syndrome Market Report:

https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

 

Some of the key facts of the Familial Chylomicronemia Syndrome Market Report:

  • The Familial Chylomicronemia Syndrome market size was valued approximately USD 15 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In May 2026, Ionis Pharmaceuticals lowered the price of Tryngolza, from USD 595,000 to USD 40,000 which is 93% reduction ahead of anticipated label expansion.

  • In January 2026, Ionis Pharmaceuticals announced TRYNGOLZA outperformed expectations as the first US FDA approved treatment for FCS, generating USD 105 million in preliminary US net product sales in 2025.

  • In September 2025, Ionis Pharmaceuticals announced that TRYNGOLZA has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed FCS. The approval is based on positive data from the Phase III Balance study, in which TRYNGOLZA 80 mg significantly reduced fasting triglycerides at 6 months, with effects sustained to 12 months, lowered acute pancreatitis events, and showed good safety and tolerability.

  • In January 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the U.S. FDA has accepted the New Drug Application (NDA) for investigational plozasiran to treat familial chylomicronemia syndrome (FCS), a rare and severe genetic disorder. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and currently does not plan to hold an advisory committee meeting. Arrowhead also plans to seek regulatory approval for plozasiran in additional regions in 2025.

  • In 2025, the US accounted for the highest diagnosed prevalent cases of FCS with more then 1,300 cases. These cases are anticipated to increase during the forecast period.

  • Approximately 70% of individuals diagnosed with FCS are male, with a median age of diagnosis around 9 years, highlighting its early onset and male predominance.

  • Japan recorded more diagnosed cases of FCS than UK.

  • In 2025, the diagnosed burden of FCS in the US was higher in the 0–17 years age group compared to individuals aged 18 years and above, indicating a greater concentration of cases in the pediatric and adolescent population.

  • Most patients (>90%) found managing fat intake to be difficult, and 53% experienced symptoms despite adherence to their diets.

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

  • The Familial Chylomicronemia Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics.

 

Familial Chylomicronemia Syndrome Overview

Familial Chylomicronemia Syndrome is a rare genetic disorder characterized by the body’s inability to properly break down fats, leading to extremely high levels of triglycerides in the blood. This condition results from a deficiency or dysfunction of lipoprotein lipase (LPL), an enzyme crucial for the metabolism of chylomicrons, which are lipoproteins that transport dietary fats in the blood.

 

To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome Market Forecast

 

Familial Chylomicronemia Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Familial Chylomicronemia Syndrome Epidemiology Segmentation:

The Familial Chylomicronemia Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of Familial Chylomicronemia Syndrome

  • Prevalent Cases of Familial Chylomicronemia Syndrome by severity

  • Gender-specific Prevalence of Familial Chylomicronemia Syndrome

  • Diagnosed Cases of Episodic and Chronic Familial Chylomicronemia Syndrome

 

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome epidemiology trends @ Familial Chylomicronemia Syndrome Epidemiology Forecast

 

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Familial Chylomicronemia Syndrome Therapies and Key Companies

  • Olezarsen (TRYNGOLZA): Ionis Pharmaceuticals and Swedish Orphan Biovitrum

  • Volanesorsen (WAYLIVRA): Ionis Pharmaceuticals

  • ARO-APOC3: Arrowhead Pharma

  • VSA001 injection: Visirna Therapeutics HK Limited

  • Olezarsen: Ionis Pharmac

  • LCQ908: Novartis

  • AKCEA-ANGPTL3-LRx: Akcea Therapeutics

  • Volanesorsen: Akcea Therapeutics

  • Plozasiran: Arrowhead Pharmaceuticals

 

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome market share @ Familial Chylomicronemia Syndrome Treatment Market

 

Familial Chylomicronemia Syndrome Market Drivers

  • Rising awareness and improved diagnosis of rare genetic lipid disorders are increasing the identification of Familial Chylomicronemia Syndrome (FCS) patients worldwide.

  • Growing prevalence of severe hypertriglyceridemia and recurrent pancreatitis is driving demand for effective targeted therapies.

  • Advancements in genetic testing and precision medicine are supporting early detection and personalized treatment approaches for FCS patients.

  • Increasing research and development activities focused on ApoC-III inhibitors and RNA-based therapies are expanding the treatment landscape.

 

Familial Chylomicronemia Syndrome Market Barriers

  • The extremely rare nature of Familial Chylomicronemia Syndrome limits the patient pool and commercial market potential.

  • High treatment costs associated with advanced biologics and gene-targeted therapies may restrict patient accessibility.

  • Delayed or misdiagnosis due to lack of disease awareness among healthcare professionals remains a major challenge.

  • Strict dietary management requirements and poor patient adherence can impact treatment outcomes.

 

Scope of the Familial Chylomicronemia Syndrome Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

  • Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies

  • Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Familial Chylomicronemia Syndrome Unmet Needs, KOL’s views, Analyst’s views, Familial Chylomicronemia Syndrome Market Access and Reimbursement

 

To know more about Familial Chylomicronemia Syndrome companies working in the treatment market, visit @ Familial Chylomicronemia Syndrome Clinical Trials and Treatment

 

Table of Contents

1. Familial Chylomicronemia Syndrome Market Report Introduction

2. Executive Summary for Familial Chylomicronemia Syndrome

3. SWOT analysis of Familial Chylomicronemia Syndrome

4. Familial Chylomicronemia Syndrome Patient Share (%) Overview at a Glance

5. Familial Chylomicronemia Syndrome Market Overview at a Glance

6. Familial Chylomicronemia Syndrome Disease Background and Overview

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Chylomicronemia Syndrome

9. Familial Chylomicronemia Syndrome Current Treatment and Medical Practices

10. Familial Chylomicronemia Syndrome Unmet Needs

11. Familial Chylomicronemia Syndrome Emerging Therapies

12. Familial Chylomicronemia Syndrome Market Outlook

13. Country-Wise Familial Chylomicronemia Syndrome Market Analysis (2022–2036)

14. Familial Chylomicronemia Syndrome Market Access and Reimbursement of Therapies

15. Familial Chylomicronemia Syndrome Market Drivers

16. Familial Chylomicronemia Syndrome Market Barriers

17. Familial Chylomicronemia Syndrome Appendix

18. Familial Chylomicronemia Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Familial Chylomicronemia Syndrome Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics